MRI or CT planning to guide high-dose-rate prostate brachytherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study randomizes men with localized prostate cancer to HDR brachytherapy planning using CT alone or CT with an MRI. The primary aim is to see if adding MRI affects acute urinary toxicity as measured by EPIC-26 urinary incontinence scores. Secondary goals include longer-term urinary irritative/obstructive symptoms, bowel and sexual domains, and physician-reported toxicity (CTCAE) for both acute and chronic periods. The trial follows participants for 12 months after treatment to compare outcomes and explore treatment efficacy between the two planning approaches.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Men ≥ 18 years old
* Histopathologically confirmed prostate cancer
* No evidence of regional or distant metastases
* Plan to undergo curative-intent HDR brachytherapy with or without external beam radiation therapy

Exclusion Criteria:

* Prior pelvic radiation therapy
* No prior prostate MRI

Where it's running

• Emory Proton Therapy Center
  Atlanta, Georgia, United States Recruiting
• Emory University Hospital Midtown
  Atlanta, Georgia, United States Recruiting
• Emory University Hospital/Winship Cancer Institute
  Atlanta, Georgia, United States Recruiting

Study contacts

• Principal investigator: Kamran Salari, MD — Emory University Hospital/Winship Cancer Institute
• Study coordinator: Kamran Salari, MD
• Email: kamran.salari@emory.edu
• Phone: 404-686-2391

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Exercise after pelvic radiation to see if it lowers colorectal cancer risk

  This study tests whether regular walking therapy after pelvic radiation for prostate cancer can influence markers of colorectal cancer in colon tissue and blood.

  Recruiting at 2 sites City of Hope Medical Center · Duarte, California and 1 other locations · NCT07790718

• Image-guided adaptive stereotactic body radiation therapy for localized prostate cancer

  This trial tests whether daily, real-time adaptive image-guided SBRT causes fewer urinary and other side effects than standard non-adaptive SBRT for men with localized prostate cancer.

  Recruiting Jonsson Comprehensive Cancer Center · Los Angeles, California · NCT07276438

• Wrapping nerves with a multi-layer perinatal tissue graft during prostate removal

  This trial will test whether wrapping the nerves with a multi-layer perinatal tissue allograft during nerve-sparing robotic prostate removal helps men with localized prostate cancer keep erectile and urinary function.

  Recruiting Mayo Clinic · Jacksonville, Florida · NCT06940271

• Testosterone therapy for men with low testosterone and localized prostate cancer on active surveillance

  This study is testing if testosterone therapy can help men with low testosterone and localized prostate cancer feel better and stay safe while they are being monitored for their cancer.

  Recruiting Phase 4 Roswell Park Cancer Institute · Buffalo, New York · NCT06733350

• Using advanced imaging to predict lymph node spread in high-risk prostate cancer

  This study is testing a new imaging method to see if it can help doctors predict whether high-risk prostate cancer has spread to lymph nodes before surgery.

  Recruiting Mayo Clinic · Jacksonville, Florida · NCT06389786

• Adaptive radiation therapy for localized prostate cancer

  This study is testing a new type of radiation therapy for localized prostate cancer to see if it can improve patients' quality of life compared to standard treatment.

  Recruiting at 5 sites Mayo Clinic · Albert Lea, Minnesota and 4 other locations · NCT06325046

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.